
Opinion|Videos|January 24, 2024
The Evolving Treatment Landscape in Relapsed/Refractory CLL
Author(s)Mazyar Shadman, MD, MPH
Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































